MARKET

KOD

KOD

Kodiak Sciences Inc.
NASDAQ
24.34
-0.42
-1.70%
After Hours: 23.83 -0.51 -2.10% 19:58 12/05 EST
OPEN
24.60
PREV CLOSE
24.76
HIGH
24.99
LOW
23.90
VOLUME
583.00K
TURNOVER
--
52 WEEK HIGH
24.99
52 WEEK LOW
1.920
MARKET CAP
1.29B
P/E (TTM)
-5.9093
1D
5D
1M
3M
1Y
5Y
1D
Kodiak Sciences: Retinal Specialist Highlights Its Top Three Programs
Seeking Alpha · 3d ago
Weekly Report: what happened at KOD last week (1124-1128)?
Weekly Report · 6d ago
Weekly Report: what happened at KOD last week (1117-1121)?
Weekly Report · 11/24 10:11
Kodiak Sciences Is Maintained at Neutral by Chardan Capital
Dow Jones · 11/17 12:24
Kodiak Sciences Price Target Maintained With a $14.00/Share by Chardan Capital
Dow Jones · 11/17 12:24
Chardan Capital Maintains Neutral on Kodiak Sciences, Maintains $14 Price Target
Benzinga · 11/17 12:14
Kodiak Sciences Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 11/17 12:03
Kodiak Sciences Price Target Raised to $26.00/Share From $24.00 by HC Wainwright & Co.
Dow Jones · 11/17 12:03
More
About KOD
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.

Webull offers Kodiak Sciences Inc stock information, including NASDAQ: KOD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KOD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KOD stock methods without spending real money on the virtual paper trading platform.